ArticleESC heart failure2021

Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines.

Victor L Mendoza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.